Pfizer ordered a halt to two phase III studies after a preliminary analysis showed that pregabalin, sold under the brand name Lyrica, was no more effective than a placebo.
In both studies — an HIV neuropathy study and a peripheral diabetic neuropathy study — patients were given Lyrica for six weeks and then switched to either a placebo or continued using Lyrica for 13 weeks. Pfizer said that patients who took Lyrica continued to show improvements, but they were not significantly different from those seen in the placebo group.
Related Articles on Pain Management:
Patients With Celiac Disease More Likely to Suffer Migraines
Pregabalin Bridges Gap in Treating Spinal Cord Injury Pain
Study Examines Why Vioxx Damaged Patients’ Hearts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
